These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 77943)

  • 21. Inhibitor of DNA polymerase in sera of tumour-bearing mice.
    Gottlieb AA; Smith AH; Plescia OJ; Persico FJ; Nicholson DE
    Nature; 1973 Dec 21-28; 246(5434):480-2. PubMed ID: 4128412
    [No Abstract]   [Full Text] [Related]  

  • 22. Cell-specific antigens and immunoglobulin synthesis of murine myeloma cells and their variants.
    Hyman R; Ralph P; Sarkar S
    J Natl Cancer Inst; 1972 Jan; 48(1):173-84. PubMed ID: 4119881
    [No Abstract]   [Full Text] [Related]  

  • 23. Structural, functional, and idiotypic characteristics of a phosphorylcholine-binding IgA myeloma protein of C57BL/ka allotype.
    Claflin JL; Rudikoff S; Potter M; Davie JM
    J Exp Med; 1975 Mar; 141(3):608-19. PubMed ID: 46916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for the existence of circulating monoclonal B-lymphocytes in multiple myeloma patients.
    Cassel A; Leibovitz N; Hornstein L; Quitt M; Aghai E
    Exp Hematol; 1990 Dec; 18(11):1171-3. PubMed ID: 2226677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.
    Muz B; de la Puente P; Azab F; Luderer MJ; King J; Vij R; Azab AK
    Br J Haematol; 2016 Apr; 173(1):70-81. PubMed ID: 26729247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.
    Hong S; Qian J; Yang J; Li H; Kwak LW; Yi Q
    Cancer Res; 2008 Oct; 68(20):8456-64. PubMed ID: 18922919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A mouse model for immunotherapy of myeloma.
    Bogen B
    Hematol J; 2002; 3(5):224-9. PubMed ID: 12391539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.
    Binsfeld M; Beguin Y; Belle L; Otjacques E; Hannon M; Briquet A; Heusschen R; Drion P; Zilberberg J; Bogen B; Baron F; Caers J
    PLoS One; 2014; 9(11):e113764. PubMed ID: 25415267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell-bound immunoglobulin on peripheral blood mononuclear cells of patients with myeloma.
    King MA; Wells JV
    Clin Exp Immunol; 1981 Sep; 45(3):552-6. PubMed ID: 6175455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological properties of myeloma proteins.
    Osterland CK; Espinoza LR
    Arch Intern Med; 1975 Jan; 135(1):32-6. PubMed ID: 46144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective effect of an interspecies hybridoma on the tumorigenicity of mouse myeloma cells.
    Baumal R; Marks A
    Cancer Res; 1981 Jul; 41(7):2598-604. PubMed ID: 7248932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro sensitization of human lymphocytes to a myeloma cell-related antigen.
    Whitson ME; Griffin GD; Novelli GD; Solomon A
    Cell Immunol; 1981 May; 60(2):489-97. PubMed ID: 6165491
    [No Abstract]   [Full Text] [Related]  

  • 33. Multiple myeloma: an immunologic profile. I. Peripheral blood studies.
    MacKenzie MR; Paglieroni T
    J Immunol; 1977 May; 118(5):1864-71. PubMed ID: 140196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myeloma proteins as tumor-specific antigens.
    Eisen HN; Sakato N; Hall SJ
    Transplant Proc; 1975 Jun; 7(2):209-14. PubMed ID: 48299
    [No Abstract]   [Full Text] [Related]  

  • 35. Radioimmunoassay for myeloma idiotype.
    Gailani S; Seon BK; Nussbaum A; Henderson ES; Pressman D
    J Natl Cancer Inst; 1977 Jun; 58(6):1553-5. PubMed ID: 405500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Problems currently most discussed regarding multiple myeloma].
    Bufano M
    Minerva Med; 1973 May; 64(35):1871-84. PubMed ID: 4123507
    [No Abstract]   [Full Text] [Related]  

  • 37. Major histocompatibility complex control of the idiotypic network in the MOPC 173 system.
    Boyer C; Schiff C; Milili M; Fougereau M
    Eur J Immunol; 1981 Oct; 11(10):769-76. PubMed ID: 6171432
    [No Abstract]   [Full Text] [Related]  

  • 38. Studies on surface antigen variants. Isolation of two complementary variants for Thy 1.2.
    Hyman R
    J Natl Cancer Inst; 1973 Feb; 50(2):415-22. PubMed ID: 4702114
    [No Abstract]   [Full Text] [Related]  

  • 39. Signaling status of IgG B cell receptor (IgG BCR) is indicative for an activated state of circulating B cells in multiple myeloma.
    Ilić V; Milosević-Jovcić N; Petrović S; Marković D; Bila J; Bosković D; Stefanović G; Marković O; Glibetić M
    Ann Hematol; 2007 Dec; 86(12):905-12. PubMed ID: 17701175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Production of monoclonal antibodies to rat MHC antigens using different myelomas.
    Misra DN; Noeman SA; Kunz HW; Gill TJ
    Transplant Proc; 1981 Jun; 13(2):1347-55. PubMed ID: 6787752
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.